Angels Share In Biotech Rewards, But Rarely In Drug Discovery

15 Oct 2012

• By Paul Bonanos

New data shows an uptick in start-up investment by individuals in young biotech and health care companies, as the contracting venture capital industry shies away from early-stage investing. But angels still avoid companies with high costs, particularly those associated with clinical and regulatory paths.

Angel investors are playing an increasingly prominent role in supporting young biotechs and health care companies, according to a new study from the University of New Hampshire’s Center for Venture Research.

The Oct. 10 report indicated that 36% of angel investments – equity investments made by high-net-worth individuals typically in start-ups...